A citation-based method for searching scientific literature

Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal.
David M Phillippo, Anthony E Ades, Sofia Dias, Stephen Palmer, Keith R Abrams, Nicky J Welton. Med Decis Making 2018
110
100

Targeting un-MET needs in advanced non-small cell lung cancer.
Niamh Coleman, Alice Harbery, Sara Heuss, Igor Vivanco, Sanjay Popat. Lung Cancer 2022
2
100


Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Conor E Steuer, Madhusmita Behera, Yuan Liu, Chao Fu, Theresa W Gillespie, Nabil F Saba, Dong M Shin, Rathi N Pillai, Suchita Pakkala, Taofeek K Owonikoko,[...]. Clin Lung Cancer 2017
33
100

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.
Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C Morris. Oncotarget 2017
25
100

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Leylah M Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka V Ikpeazu. J Hematol Oncol 2021
5
100

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
222
100

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
142
100

MEK inhibitors for the treatment of non-small cell lung cancer.
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang. J Hematol Oncol 2021
44
100

Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.
James E Signorovitch, Vanja Sikirica, M Haim Erder, Jipan Xie, Mei Lu, Paul S Hodgkins, Keith A Betts, Eric Q Wu. Value Health 2012
170
100

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
Patricia Guyot, A E Ades, Mario J N M Ouwens, Nicky J Welton. BMC Med Res Methodol 2012
932
100

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Paula Chu, Miranta Antoniou, Mohit K Bhutani, Amine Aziez, Monica Daigl. J Comp Eff Res 2020
5
100

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
12
100

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
20
100

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
715
100

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Cancers (Basel) 2020
8
100

Simulation and matching-based approaches for indirect comparison of treatments.
K Jack Ishak, Irina Proskorovsky, Agnes Benedict. Pharmacoeconomics 2015
40
100

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Lung Cancer 2021
5
100

Savolitinib: First Approval.
Anthony Markham. Drugs 2021
7
100

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
934
100

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
246
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.